Novo Nordisk alleged that Hims & Hers is putting patient safety at risk by selling compounded versions of Wegovy. Novo's ...

The Danish pharmaceutical said it was ending the partnership because Hims is selling and promoting a cheaper copycat of its ...

The stock's market-beating momentum has come crashing to a halt, following shocking allegations from one of the world's largest pharmaceutical companies.

Novo Nordisk had been providing Hims & Hers with the FDA-approved Wegovy used for weight loss since late April in order to ...

Novo Nordisk ended a short-lived agreement to sell its Wegovy weight-loss drug through Hims & Hers Health on Monday, sending ...

Novo Nordisk is ending a partnership with Hims & Hers. The fallout comes over claims the telehealth platform sold copycat versions of the pharmaceutical giant’s weight-loss drug Wegovy. The ...

Hims & Hers ( HIMS) stock plummeted around 30% in early trading Monday after Novo Nordisk ( NVO) announced it was ending a collaboration to make its blockbuster weight-loss drug, Wegovy, available on ...

A bundled offering of Novo Nordisk’s FDA-approved Wegovy® on the Hims & Hers platform marks the first step in a long-term collaboration roadmap, pairing innovative treatments with a leading ...

The fortune of the San Francisco-based telehealth company’s cofounder and chief executive, Andrew Dudum, crumbled by more ...

Hims & Hers Stock Drops More Than 30% After Novo Nordisk Breakup Wegovy maker cuts ties with telehealth company, citing allegations of deceptive marketing practices and drug compounding By ...

On April 29, Novo Nordisk (NYSE: NVO) and Hims & Hers Health (NYSE: HIMS) announced they were collaborating to allow Hims & Hers to sell the weight-loss drug Wegovy. Hims & Hers stock soared on ...

However, recently, pharmaceutical giant Novo Nordisk, the maker of popular GLP-1 agonist weight loss drug Wegovy, terminated its sales partnership with the company due to its continued efforts to ...